Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

C3-Luc Cells Are an Excellent Model for Evaluation of Cellular Immunity following HPV16L1 Vaccination.

Li LL, Wang HR, Zhou ZY, Luo J, Wang XL, Xiao XQ, Zhou YB, Zeng Y.

PLoS One. 2016 Feb 22;11(2):e0149748. doi: 10.1371/journal.pone.0149748. eCollection 2016.

2.

Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids.

Handisurya A, Schellenbacher C, Haitel A, Senger T, Kirnbauer R.

Br J Cancer. 2016 Feb 16;114(4):409-16. doi: 10.1038/bjc.2015.462. Epub 2016 Feb 11.

3.

Monocyte unresponsiveness and impaired IL1β, TNFα and IL7 production are associated with a poor outcome in Malawian adults with pulmonary tuberculosis.

Waitt CJ, Banda P, Glennie S, Kampmann B, Squire SB, Pirmohamed M, Heyderman RS.

BMC Infect Dis. 2015 Nov 13;15:513. doi: 10.1186/s12879-015-1274-4.

4.

Immune status of patients with inherited bone marrow failure syndromes.

Giri N, Alter BP, Penrose K, Falk RT, Pan Y, Savage SA, Williams M, Kemp TJ, Pinto LA.

Am J Hematol. 2015 Aug;90(8):702-8. doi: 10.1002/ajh.24046. Epub 2015 May 28.

5.

Association between tumor necrosis factor alpha rs1800629 polymorphism and risk of cervical cancer.

Wang L, Ma K, Wang Z, Mou Y, Ma L, Guo Y.

Int J Clin Exp Med. 2015 Feb 15;8(2):2108-17. eCollection 2015.

6.

Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.

Liu Y, Zhou J, Yu Z, Fang D, Fu C, Zhu X, He Z, Yan H, Jiang L.

BMC Microbiol. 2014 Dec 18;14:233. doi: 10.1186/s12866-014-0233-3.

7.

Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.

Herrin DM, Coates EE, Costner PJ, Kemp TJ, Nason MC, Saharia KK, Pan Y, Sarwar UN, Holman L, Yamshchikov G, Koup RA, Pang YY, Seder RA, Schiller JT, Graham BS, Pinto LA, Ledgerwood JE.

Hum Vaccin Immunother. 2014;10(12):3446-54. doi: 10.4161/hv.34408.

8.

Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children.

Weinberg A, Song LY, Saah A, Brown M, Moscicki AB, Meyer WA 3rd, Bryan J, Levin MJ; IMPAACT/PACTG P1047 Team.

J Infect Dis. 2012 Oct;206(8):1309-18. Epub 2012 Aug 2.

9.

Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice.

Zhang S, Liang M, Gu W, Li C, Miao F, Wang X, Jin C, Zhang L, Zhang F, Zhang Q, Jiang L, Li M, Li D.

Virol J. 2011 Jun 30;8:333. doi: 10.1186/1743-422X-8-333.

10.

Human papillomavirus disease and vaccines in adolescents.

Moscicki AB.

Adolesc Med State Art Rev. 2010 Aug;21(2):347-63, x-xi. Review.

11.

Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining.

Smith SG, Lalor MK, Gorak-Stolinska P, Blitz R, Beveridge NE, Worth A, McShane H, Dockrell HM.

BMC Immunol. 2010 Jul 7;11:35. doi: 10.1186/1471-2172-11-35.

12.

Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.

Graham BS, Kines RC, Corbett KS, Nicewonger J, Johnson TR, Chen M, LaVigne D, Roberts JN, Cuburu N, Schiller JT, Buck CB.

Mucosal Immunol. 2010 Sep;3(5):475-86. doi: 10.1038/mi.2010.31. Epub 2010 Jun 16.

13.

Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses.

Senger T, Becker MR, Schädlich L, Waterboer T, Gissmann L.

J Virol. 2009 Dec;83(24):12692-701. doi: 10.1128/JVI.01582-09. Epub 2009 Sep 30.

14.

Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients.

García-Piñeres AJ, Hildesheim A, Dodd L, Kemp TJ, Yang J, Fullmer B, Harro C, Lowy DR, Lempicki RA, Pinto LA.

J Immunol. 2009 Feb 1;182(3):1706-29.

15.

Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles.

Buonaguro L, Tornesello ML, Gallo RC, Marincola FM, Lewis GK, Buonaguro FM.

J Virol. 2009 Jan;83(1):304-13. doi: 10.1128/JVI.01606-08. Epub 2008 Oct 22.

16.

HPV Vaccines: today and in the Future.

Moscicki AB.

J Adolesc Health. 2008 Oct;43(4 Suppl):S26-40. doi: 10.1016/j.jadohealth.2008.07.010. Review.

17.

Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity.

Bozza FA, Cruz OG, Zagne SM, Azeredo EL, Nogueira RM, Assis EF, Bozza PT, Kubelka CF.

BMC Infect Dis. 2008 Jun 25;8:86. doi: 10.1186/1471-2334-8-86.

18.

Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.

García-Piñeres A, Hildesheim A, Dodd L, Kemp TJ, Williams M, Harro C, Lowy DR, Schiller JT, Pinto LA.

Clin Vaccine Immunol. 2007 Aug;14(8):984-9. Epub 2007 Jun 27.

19.

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.

Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, Christensen ND, Roden RB, Kirnbauer R.

Vaccine. 2007 Mar 1;25(11):2001-10. Epub 2006 Nov 29.

20.

Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice.

Zamora E, Handisurya A, Shafti-Keramat S, Borchelt D, Rudow G, Conant K, Cox C, Troncoso JC, Kirnbauer R.

J Immunol. 2006 Aug 15;177(4):2662-70.

Supplemental Content

Support Center